金斯瑞生物科技(01548.HK):傳奇生物(LEGN.US)終止與Noile合作研究協議
金斯瑞生物科技(01548.HK)公布,非全資附屬公司「傳奇生物科技」(LEGN.US)公告,由於雙方未能共同協定選擇用於進一步研究的抗原靶點,美國傳奇與Noile決定終止2020年4月27日的合作研究及許可協議,自2022年1月28日起生效,該協議涉及結合Noile運用細胞分泌白細胞介素7(IL7)和趨化因子配體19(CCL19)的PRIME(誘導增殖及促進遷移)技術,開發嵌合抗原受體(CAR-T)及/或T細胞受體(TCR-T)療法。公司未有向Noile支付任何款項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.